| Literature DB >> 33119882 |
Dário Ligeiro1, Martin Rao2, Andreia Maia3, Mireia Castillo3, Antonio Beltran3, Markus Maeurer4,5.
Abstract
We review state-of-the-art in translational and clinical studies focusing on the tumor microenvironment (TME) with a focus on tumor-infiltrating B cells (TIBs). The TME is a dynamic matrix of mutations, immune-regulatory networks, and distinct cell-to-cell interactions which collectively impact on disease progress. We discuss relevant findings concerning B cells in pancreatic cancer, the concepts of "bystander" B cells, the role of antigen-specific B cells contributing to augmenting anticancer-directed immune responses, the role of B cells as prognostic markers for response to checkpoint inhibitors (ICBs), and the potential use in adoptive cell tumor-infiltrating lymphocyte (TIL) products.Entities:
Keywords: Adjuvant therapy; Antibody; B cells; Breg; CDR3; Chemotherapy; Complement; Cytokines; ICB; Immune checkpoint inhibition; Immune responses; Immunosuppression; Inflammation; Pancreatic cancer; Prognostic markers; RNA profiling; TIB; TIL; Therapy
Mesh:
Year: 2020 PMID: 33119882 DOI: 10.1007/978-3-030-49270-0_10
Source DB: PubMed Journal: Adv Exp Med Biol ISSN: 0065-2598 Impact factor: 2.622